美容护理 2025 年 05 月 11 日 聚美丽大会指引美业发展，国际集团在华触底反弹 行 业 及 产 业 看好 ——化妆品医美行业周报 20250511 本期投资提示： 券 研 究 报 告 证券分析师 王立平 A0230511040052 wanglp@swsresearch.com 王盼 A0230523120001 wangpan@swsresearch.com 聂霜 A0230524120002 nieshuang@swsresearch.com 联系人 王立平 (8621)23297818× wanglp@swsresearch.com 本研究报告仅通过邮件提供给 中庚基金 使用。1 请务必仔细阅读正文之后的各项信息披露与声明 行 业 研 究 / 行 业 点 评 证 相关研究 - ⚫ 本周化妆品医美板块表现弱于市场，涨后回调。2025 年 4 月 30 日至 2025 年 5 月 9 日期间，申万美容护理指数上涨 1.7%，弱于申万 A 指数 0.6pct。其中，申万化妆品指 数上涨 2.8%，强于申万 A 指 0.5pct；申万个护用品指数上涨 2.3%，与申万 A 指基本 持平。 ⚫ 周观点： ...

沪指5月9日下跌0.30%，申万所属行业中，今日上涨的有7个，涨幅居前的行业为美容护理、银行，涨 幅分别为1.41%、1.36%。美容护理行业位居今日涨幅榜首位。跌幅居前的行业为电子、计算机，跌幅 分别为2.07%、1.96%。 | 代码 | 简称 | 今日涨跌幅（%） | 今日换手率（%） | 主力资金流量（万元） | | --- | --- | --- | --- | --- | | 002094 | 青岛金王 | -4.17 | 23.74 | -4096.76 | | 603193 | 润本股份 | 4.77 | 5.32 | -868.93 | | 300856 | 科思股份 | -0.10 | 1.41 | -840.98 | | 603983 | 丸美生物 | 5.38 | 1.38 | -801.90 | | 301009 | 可靠股份 | -1.81 | 4.65 | -779.05 | | 300896 | 爱美客 | -0.38 | 1.26 | -750.74 | | 300132 | 青松股份 | 0.18 | 2.76 | -553.39 | | 002511 | 中顺洁柔 | 1 ...

金融界5月8日消息，上证指数低开高走，中证全指医疗保健设备与服务指数 (医疗保健，H30178)上涨 0.39%，报13367.74点，成交额146.35亿元。 数据统计显示，中证全指医疗保健设备与服务指数近一个月上涨5.82%，近三个月下跌2.05%，年至今 下跌2.72%。 据了解，中证全指医疗保健设备与服务指数从中证全指指数中选取与医疗保健主题相对应的行业内上市 公司证券作为指数样本，以反映该主题上市公司证券的整体表现。该指数以2004年12月31日为基日，以 1000.0点为基点。 从指数持仓来看，中证全指医疗保健设备与服务指数十大权重分别为：迈瑞医疗（9.57%）、爱尔眼科 （8.34%）、联影医疗（7.63%）、爱美客（3.55%）、惠泰医疗（3.28%）、鱼跃医疗（2.88%）、新产 业（2.81%）、美年健康（2.35%）、乐普医疗（2.07%）、九安医疗（2.03%）。 从中证全指医疗保健设备与服务指数持仓的市场板块来看，深圳证券交易所占比60.66%、上海证券交 易所占比39.34%。 从中证全指医疗保健设备与服务指数持仓样本的行业来看，医疗设备占比34.34%、医疗耗材占比 27.26% ...

医药生物行业 超配（维持） Q1 板块业绩承压，关注细分景气方向 医药生物行业 2024 年及 2025 年一季度业绩综述 投资要点： 本报告的风险等级为中高风险。 本报告的信息均来自已公开信息，关于信息的准确性与完整性，建议投资者谨慎判断，据此入市，风险自担。 请务必阅读末页声明。请务必阅读末页声明。 分析师：谢雄雄 SAC 执业证书编号： S0340523110002 电话：0769-22110925 邮箱： 分析师：魏红梅 SAC 执业证书编号： S0340513040002 电话：0769-22119462 邮箱：whm2@dgzq.com.cn 医药生物（申万）指数走势 资料来源：东莞证券研究所，Wind 相关报告 证 券 研 究 报 告 业 绩 综 述 行 业 研 究 2025 年 5 月 8 日 xiexiongxiong@dgzq.com.cn ◼ 2024年行业整体营收和归母净利润同比有所下滑。2024年，SW（2021）医 药生物行业实现营业总收入2.46万亿元，同比下滑1.0%，增速同比下滑1.8 个百分点；实现归属于母公司股东的净利润1,402.6亿元，同比下降13.1%， 增速同比上 ...

证券研究报告 悦享生活，深挖情绪消费景气赛道 零售行业2025年中期投资策略 姓名 黄泽鹏（分析师） 证书编号：S0790519110001 邮箱：huangzepeng@kysec.cn 核心观点 姓名 陈思（联系人） 证书编号：S0790124070031 邮箱：chensi@kysec.cn 1.行业回顾 2025Q1社会消费复苏缓慢，零售企业经营整体承压。具体分板块看，黄金珠宝受金价高涨影响动销，跨境电商收入稳健、利润承压， 医美化妆品竞争激烈，线下零售企业更多还处在模式变革探索阶段。值得注意的是，部分与"情绪价值"消费相关的细分赛道，对应 龙头品牌型企业，一季度经营情况已显著优于行业整体。 姓名 姚慕宇（联系人） 证书编号：S0790125040021 邮箱：yaomuyu@kysec.cn 2025年5月7日 2. 细分板块梳理分析 3. 投资建议 黄金珠宝：品牌格局分化，关注具备差异化产品力和消费者深度洞察力的黄金珠宝品牌，重点推荐老铺黄金、潮宏基、周大生等。 线下零售：看好顺应趋势积极变革探索的零售企业（超市、百货、连锁），重点推荐永辉超市、爱婴室等，受益标的重庆百货等。 化妆品：看好"高景气 ...

证券研究报告 社会服务行业周报 五一出行"多点开花"， 即时零售热度升级 社会服务行业 强于大市（维持） 核心摘要 平安证券研究所 新消费团队 分析师：胡琼方 S1060524010002（证券投资咨询） 邮箱：huqiongfang722@pingan.com.cn 2025年05月06日 请务必阅读正文后免责条款 3 据人民日报客户端，5月1日至5日，预计全社会跨区域人员流动量累计14.67亿人次，日均2.93亿人次，同比增长 8.0%。其中：铁路客运量累计10169.2万人次，日均2033.8万人次，同比增长10.8%。公路人员流动量(包括高速公路 及普通国省道非营业性小客车人员出行量、公路营业性客运量)累计13.45亿人次，日均2.69亿人次，同比增长7.6%。 水路客运量累计868.9万人次，日均173.8万人次，同比增长24.9%。民航客运量累计1114.3万人次，日均222.9万人次， 同比增长11.8%。 据携程黑板报公众号，五一假期长线游目的地表现亮眼，青海、新疆、宁夏等地景区门票销售额同比激增1-2倍；亲 子家庭与携宠出游"双线并进"；自驾游市场"量价齐升" ，异地出行占比达85%；邮轮游 ...

Group 1 - The core viewpoint of the articles highlights the declining financial performance of the company, with a significant drop in revenue and net profit in Q1 2025 compared to the previous year [1][2] - In 2024, the company reported a revenue of 30.26 billion yuan, a year-on-year increase of 5.45%, and a net profit of 19.58 billion yuan, also up 5.33%, marking the lowest growth rates since 2016 [1][2] - The company announced a substantial dividend plan, distributing 38 yuan per 10 shares, totaling 1.145 billion yuan, which represents 58.51% of its net profit [1] Group 2 - The company's main revenue sources are solution and gel injection products, with solution products generating 17.44 billion yuan and gel products 12.16 billion yuan in 2024, both showing positive growth but at a significantly reduced rate [2] - The market for hyaluronic acid is becoming increasingly competitive, with 59 approved injection products by the end of 2023, leading to price wars that compress profit margins [2] - The overall growth rate of the medical beauty industry has decreased from over 20% in 2023 to approximately 10% in 2024, with declining consumer frequency and average transaction value adding to market pressures [2] Group 3 - To address growth challenges, the company is diversifying its operations, increasing R&D spending to 3.04 billion yuan in 2024, which is 10.04% of its revenue, focusing on products like botulinum toxin and semaglutide injections [3] - The company acquired 85% of the South Korean regenerative medical company REGEN for 1.373 billion yuan, gaining access to its global distribution network, although the high premium raised concerns about goodwill risk [3] - The company is also venturing into the health sector with a weight management product, "Supermodel Pill," aiming to replicate the market success of GLP-1 drugs, despite potential operational challenges [3] Group 4 - The short-term outlook for the hyaluronic acid market is constrained by stricter regulations, intensified competition, and more rational consumer behavior, limiting growth opportunities for traditional products [4] - Long-term prospects may improve if the company's investments in regenerative materials and weight loss drugs are successfully commercialized, potentially opening new growth avenues [4] - The company's international expansion efforts are in early stages, with overseas revenue of only 1.58 million yuan in 2024, but leveraging REGEN's qualifications in 34 countries could enhance market opportunities [4]

Core Viewpoint - The company experienced a revenue decline in Q1 2025 due to a high base from the previous year, but showed slight sequential growth compared to Q4 2024, indicating a gradual recovery in consumer spending [1] Financial Performance - In Q1 2025, the company reported revenue of 660 million yuan, a decrease of 17.9% year-on-year, but a slight increase of 1.5% quarter-on-quarter from 650 million yuan in Q4 2024 [1] - The gross margin remained relatively stable at 93.9%, with operating expense ratios increasing due to a decline in revenue and new R&D investments [1] - The net profit for Q1 2025 was 440 million yuan, down 15.9% year-on-year, but the net profit margin improved to 66.9%, an increase of 1.6 percentage points, primarily due to significant gains from fair value changes in investments and increased other income [1] Acquisition and Growth Potential - The company announced plans to acquire 85% of South Korean REGEN for 190 million USD, which is expected to significantly contribute to revenue and profit starting in 2026 [2] - REGEN reported revenue of 72.23 million yuan and net profit of 29.5 million yuan for the first nine months of 2024, with plans to expand production capacity [2] Earnings Forecast and Valuation - The company forecasts revenues of 3.3 billion yuan and 3.6 billion yuan for 2025 and 2026, respectively, with year-on-year growth rates of 9.2% and 9.1% [3] - Projected net profits for the same years are 2.02 billion yuan and 2.18 billion yuan, with growth rates of 3.1% and 7.7% [3] - The target price is set at 299.47 yuan per share, reflecting a price-to-earnings ratio of 45x for 2025 and 42x for 2026, emphasizing the company's strong brand and channel advantages [3]

行 业 研 究 2025 年 05 月 05 日 投资评级：看好（维持） 行业走势图 数据来源：聚源 -29% -14% 0% 14% 29% 43% 2024-05 2024-09 2025-01 商贸零售 沪深300 相关研究报告 《年报一季报陆续披露，关注高景气 板块优质公司—行业周报》-2025.4.27 《"美团闪购"品牌独立，即时零售模 式加速发展—行业周报》-2025.4.20 《医美化妆品 3 月月报：锦波生物首 个胶原蛋白填充三类械获批，关注"情 绪消费"主线下的美妆机遇—行业点 评报告》-2025.4.19 零售企业经营持续承压，关注高景气优质公司 ——行业周报 | 黄泽鹏（分析师） | 陈思（联系人） | | --- | --- | | huangzepeng@kysec.cn | chensi@kysec.cn | | 证书编号：S0790519110001 | 证书编号：S0790124070031 | chensi@kysec.cn 证书编号：S0790124070031 财报全部披露完毕，零售企业经营持续承压，关注高景气板块优质公司 A 股上市公司 2024 年年报、2025 年 ...

Investment Rating - The report maintains an "Outperform" rating for the company [1][2][16]. Core Views - The company experienced a revenue decline of 17.9% year-on-year in Q1 2025 due to a high base effect, with revenue reported at RMB 660 million. However, there was a slight quarter-on-quarter growth of 1.5% compared to Q4 2024 [3][11]. - The gross margin remained stable at 93.9%, while operating expenses increased due to higher sales, administrative, and R&D expense ratios [12]. - Non-recurring gains offset the revenue decline, leading to a net profit of RMB 440 million, down 15.9% year-on-year, with a net profit margin of 66.9% [13]. - The company is planning to acquire 85% of South Korean company REGEN, which is expected to significantly contribute to revenue and profits starting in 2026 [14][16]. - Revenue and net profit forecasts for 2025 and 2026 are projected at RMB 3.30 billion and RMB 3.60 billion, and RMB 2.02 billion and RMB 2.18 billion respectively, indicating year-on-year growth of 9.2% and 9.1% for revenue, and 3.1% and 7.7% for net profit [15][16]. Financial Summary - For 2025, the company is expected to achieve revenue of RMB 3.30 billion and net profit of RMB 2.02 billion, with respective growth rates of 9.2% and 3.1% [15]. - The projected diluted EPS for 2025 is RMB 6.67, with a P/E ratio of 26 [5][9]. - The company maintains a strong gross profit margin of 94.6% for 2025, with a projected return on equity (ROE) of 20.6% [5][9].